Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab biosimilar for brain metastases in breast cancer: real-world study
ChiCTR2200061141Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in breast cancer with brain metastasis (BCBM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: intracranial progress free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
breast cancer with brain metastasis (BCBM)
Beyond the preview
Go deeper on ChiCTR2200061141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061141.